Back to News
Market Impact: 0.3
Innovent Announces Phase 3 RESTORE-3 Study of SYCUME® (Teprotumumab N01 Injection) Met Primary Endpoint in Inactive Thyroid Eye Disease
Source: PR Newswire
Healthcare & Biotech
Innovent Biologics reported that SYCUME improved proptosis in participants with inactive thyroid eye disease, with a 60.4% response rate and a least-squares mean change from baseline of -1.88 mm. The company also described the safety profile as favorable; the excerpt provides no further study details or market reaction.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
moderately positive
Sentiment Score
0.40
More News
- Teva wins FDA approval for monthly schizophrenia injection Weltruza
- BofA downgrades Alignment Healthcare stock rating on star rating drop
- Humana Stock Jumps on Raised Medicare Advantage Ratings
- Premarket movers: Humana rallies; SpaceX deal sends telco stocks down
- HIMS jumps 7% on peptide tailwind — but Citi sees 17% downside from here
- Alignment Healthcare Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into Alignment Healthcare (ALHC)